A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

August 31, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2020

Conditions

Hospital-Acquired Bacterial PneumoniaVentilator-Associated Bacterial PneumoniaHospital-Acquired PneumoniaVentilator-Associated Pneumonia

Interventions

DRUG

Meropenem-Vaborbactam

meropenem 2 g and vaborbactam 2 g

DRUG

Piperacillin/Tazobactam

piperacillin 4 g and tazobactam 0.5 g